Overview:

This is an in-depth course on kidney cancer covering the latest advances in laparoscopic treatment in patients with localized as well as advanced disease and recent advances in partial nephrectomy and minimally invasive techniques. It will cover the current strategies for systemic treatment of patients with advanced kidney cancer, emphasizing the role of the urologic surgeon in the management of such patients. The course will also cover the recent advances in our understanding of the genetic basis of kidney cancer and how this knowledge is changing the way we think about diagnosis and treatment of kidney cancer. There are new approaches for the management of localized, locally advanced and advanced renal cell carcinoma that the practicing urologic surgeon is not knowledgeable about.

Objectives: After attending this course, the participants should be able to:

• review the recent advances in therapy of patients with advanced kidney cancer, including the use of the new, recently approved molecular-based therapies, immunotherapies, anti-angiogenesis therapies and stem cell therapy
• discuss the natural history of kidney cancer and the role of surgical intervention
• state the genes that cause kidney cancer and why they are important to the clinical practice of the urologic surgeon for diagnosis and management of this disease
• describe the recent advances in surgical treatment, including management of tumor in the vena cava, partial nephrectomy, laparoscopic nephrectomy and other forms of minimally invasive therapy, such as RFA, for treatment of localized, locally advanced as well as advanced kidney cancer
• practice continued follow-up care of patients with both sporadic as well as inherited forms of cancer of the kidney

If you wish to apply for CME for these lectures, please log in first.